Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, our findings provide no evidence indicating that SNP344A may affect MDM2 transcription or cancer risk.
|
22558411 |
2012 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A functional variant in the MDM2 gene promoter, single-nucleotide polymorphism 309 (SNP309) T > G (rs2279744), has been reported to cause an increase in MDM2 protein levels and impairment of p53 tumor suppressor activity, which may be associated with the development of cancer.
|
24792886 |
2014 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The higher prevalence of MDM2 SNP309 homozygous G/G carriers in the TP53-negative group suggests that this allele contributes to cancer susceptibility in LFS and LFS-related families.
|
17003841 |
2007 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This would incorporate key intracellular signalling pathways associated with cancer within each cell (e.g. p53-Mdm2, NF-[Formula: see text]B) and through the use of high-performance computing be capable of simulating up to [Formula: see text] cells, i.e. the tissue scale.
|
28634857 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The SNPs Arg72Pro of TP53 and T309G of MDM2 have been associated with many cancer types and have been differently distributed among populations worldwide.
|
23661019 |
2013 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data provide causal evidence for increased cancer risk in carriers of the Mdm2(SNP309G) allele.
|
20832750 |
2010 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A single-nucleotide polymorphism (SNP) in the promoter of the MDM2 gene, SNP309 (a T-->G change), was recently implicated in the early onset of cancer in individuals with Li-Fraumeni syndrome and of sporadic soft-tissue sarcoma.
|
16478747 |
2006 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Studies of human genetic variants in the p53 tumor suppressor gene and MDM2 oncogene have shown that single nucleotide polymorphisms (SNP) can affect p53 signaling, confer cancer risk, and alter outcome, and also suggest that the pathway is under evolutionary selective pressure.
|
19773383 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The Study of MDM2 rs937283 Variant and Cancer Susceptibility in a Central Chinese Population.
|
30244662 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Although it needs further evaluations, obtained results strengthen the role of MDM2 SNP309 as a genetic factor in hereditary predisposition to cancer, so improving LFS Suggestive patients management.
|
26956143 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk.
|
25316267 |
2014 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, our results suggest that MDM2 SNP 309 may contribute to the LFL phenotype and also to an earlier age at diagnosis of ACC and BC cancer in carriers of the R337H founder mutation.
|
28756477 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The common T309G polymorphism of Mdm2 has been the most frequently investigated, which can influence in cancer susceptibility and disease outcome.
|
18348658 |
2008 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Based on the key role of p53 and MDM2 in tumor suppression, polymorphisms that cause change in their function might affect cancer risk.
|
25227851 |
2014 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recent studies have shown that functional polymorphisms at the MDM2 SNP309 T/G and p53 Arg72Pro may be associated with cancer susceptibility.
|
18575717 |
2008 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Currently, the MDM2 promoter rs937283 A > G variant that is able to alter MDM2 gene expression has been widely studied to explore the association of MDM2 with cancer risk.
|
29777315 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
P53 codon 72 and MDM2 309T>G polymorphisms could influence p53 and MDM2 function, respectively, and might affect cancer susceptibility.
|
26476535 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Although we cannot exclude that alterations in MDM2 preferentially occur during cancer development, our data rather indicate that in this context the commonly observed transcript variants may also possess a normal physiological function.
|
14654951 |
2004 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recent data suggest that a promoter polymorphism in the MDM2 gene may influence age of cancer onset in a gender-specific fashion.
|
17171684 |
2007 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
|
17116689 |
2007 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The MDM2 SNP309 has been associated with increased expression of the protein which could suppress p53 function, and has been shown to modulate risk to cancer.
|
18804411 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We have therefore analysed, in a pilot study, whether the status of MDM2 SNP309 and p53 codon-72 polymorphism, which was also shown to affect cancer predisposition, would affect cancer risk, onset age, overall survival and response to therapy in Chinese leukaemia patients. p53 SNP was not associated with any of the parameters.
|
18313915 |
2008 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Three MDM2 SNPs(rs937283, rs2270744 and rs769412) have previously been suggested to be positively correlated with cancer.
|
27506496 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The mouse double minute 2 (MDM2) gene plays a key role in the p53 pathway, and the SNP 309T/G single- nucleotide polymorphism in the promoter region of MDM2 has been shown to be associated with increased risk of cancer.
|
23167337 |
2012 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Murine double-minute 2 (MDM2) oncoprotein plays a pivotal role in regulating p53, and the single-nucleotide polymorphism (SNP) 309T/G SNP in the promoter region of Mdm2 has been shown to be associated with increased risk of cancer.
|
24325471 |
2014 |